JUAN JOSÉ
LAHUERTA PALACIOS

Investigador ata 2020

Foto de JUAN JOSÉ

Foto de Hospital Miguel Servet

Hospital Miguel Servet

Zaragoza, España

Publicacións en colaboración con investigadores/as de Hospital Miguel Servet (5)

2024

Immunoparesis recovery in newly diagnosed transplant ineligible multiple myeloma patients, an independent prognostic factor that complements minimal residual disease
Annals of Hematology

2022

Lenalidomide-dexamethasone versus observation in high-risk smoldering myeloma after 12 years of median follow-up time: A randomized, open-label study
European Journal of Cancer, Vol. 174, pp. 243-250

2016

Immune status of high-risk smoldering multiple myeloma patients and its therapeutic modulation under lendex: A longitudinal analysis
Blood, Vol. 127, Núm. 9, pp. 1151-1162
Lenalidomide plus dexamethasone versus observation in patients with high-risk smouldering multiple myeloma (QuiRedex): long-term follow-up of a randomised, controlled, phase 3 trial
The Lancet Oncology, Vol. 17, Núm. 8, pp. 1127-1136

2011

Lenalidomide is effective as salvage therapy in refractory or relapsed multiple myeloma: Analysis of the Spanish compassionate use registry in advanced patients
International Journal of Hematology, Vol. 93, Núm. 3, pp. 351-360